Select a community
MS
Find out more about the PatientsLikeMe
MS Community
Home > Community Treatment Reports > Rozerem Treatment Report
What is Rozerem?

Rozerem is a brand name for the drug Ramelton, a melatoninergic prescription sleep aid used in the treatment of insomnia. Read more...Click to read more below

Takeda Pharmaceuticals's Rozerem site

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Insomnia 12 1
Other 7 0
Awakening due to pain 2 0
Fatigue 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
1 100%
None
0 0%

Most commonly reported side effects

feeling drugged
1 100%
  • Mild
  • Moderate
  • Severe

Dosages

  10mg as needed 8mg as needed mg as needed 8 mg daily 10 daily
  1 Number of Patients: 1 3 Number of Patients: 3 1 Number of Patients: 1 9 Number of Patients: 9 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Rozerem (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work
5 100% Did not seem to work: 100%
Course of treatment ended
1 20% Course of treatment ended: 20%

See all 5 patients who’ve stopped taking Rozerem

Duration See details about how long patients take this treatment ▼

Currently Taking Rozerem

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
2
2
3
0

Stopped Taking Rozerem

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
4
0
0
1
0
0

Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Always
1 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
1 100%
Not at all
0 0%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 21, 2009.